Ionizable Cationic Lipid for Stable RNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid therapeutics face challenges in achieving stable formulations with long shelf-life and efficient intracellular delivery, particularly in anhydrous organic or polar aprotic solvents, which limits their therapeutic effectiveness due to side-reactions in aqueous or nonpolar solvents.
Innovation Solution
Development of novel lipid compositions and pharmaceutical compositions that form lipid nanoparticles, enabling the targeted intracellular delivery of biologically active molecules, such as RNA polynucleotides, by encapsulating them in a stable form to prevent degradation and enhance circulation lifetime.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nucleic acids are formulated in aqueous or nonpolar solvents, then they can be delivered to target cells, but side-reactions occur that reduce stability and shelf-life
Solution Approach 1:
The patent uses anhydrous organic solvents or anhydrous polar aprotic solvents as an inert environment to formulate nucleic acids, preventing side-reactions that occur in aqueous or nonpolar solvents. This inert formulation environment maintains stability and extends shelf-life while enabling subsequent delivery to target cells.
2Reliability
If conventional lipid formulations are used, then nucleic acids can be encapsulated, but delivery efficiency to targeted cells is limited
Solution Approach 1:
The patent modifies lipid composition parameters including charge density, hydrophobicity, and molecular structure to create optimized lipid formulations. These parameter changes enable the lipids to effectively encapsulate nucleic acids and facilitate efficient delivery to targeted cells by altering cellular uptake mechanisms.
Solution Approach 2:
The patent employs composite lipid formulations combining multiple lipid types with complementary properties. This composite approach creates formulations that simultaneously provide stable encapsulation and enhanced cellular delivery efficiency, overcoming limitations of single-component systems.
3Duration of action of moving object
If nucleic acids are delivered without specialized formulations, then the process is simple, but circulation lifetime is short and therapeutic effectiveness is reduced
Solution Approach 1:
The patent optimizes physical and chemical parameters of the formulation including particle size, charge, and composition to extend circulation lifetime. These parameter adjustments protect nucleic acids from degradation and enhance stability in biological environments without requiring overly complex formulation strategies.
Data Source
AI summary
Disclosed herein is a compound of Formula I, wherein R1 is a branched chain alkyl consisting of 10 to 31 carbons; R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons; L1 and L2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons; X1 is S or O; R3 is a linear or branched alkylene consisting of 1 to 6 carbons; and R4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt or solvate thereof.